Cannabis comp tables as of Dec. 2, 2019

This comp table provides a benchmark for private investors to evaluate existing and future investments as well as a menu for public investors to peruse.

Cannabis comp tables as of Nov. 25, 2019

This comp table provides a benchmark for private investors to evaluate existing and future investments as well as a menu for public investors to peruse.

Harvest Health & Harborside cut guidance, MORE Act passes congressional committee & more

The week was busy with earnings misses and beats, legislative progress, contract and deal adjustments as well as reduced expectations.

Cannabis comp tables as of Nov. 18, 2019

This comp table provides a benchmark for private investors to evaluate existing and future investments as well as a menu for public investors to peruse.

Who’s the next Aurora? Debt due near term is equity

As cannabis company fundamentals weaken and capital gets tighter, common equity investors need to recognize the possibility of major dilution from the equitization of debt that is due soon. This raises the cost of equity for any companies with debt.

Cannabis comp tables – now with EV/EBITDA – as of Nov. 11, 2019

This comp table provides a benchmark for private investors to evaluate existing and future investments as well as a menu for public investors to peruse.

Catalyst Calendar: Nov. 11, 2019

The cannabis industry changes so rapidly that investors must always be aware of new information. This catalyst calendar provides you with key events that may impact your investments and investment decisions over the next month.

Portugal tries to position itself as Europe’s top medical cannabis exporter, but companies face challenges

Portugal is gearing up to become a medical marijuana production powerhouse serving growing European markets.

Cannabis comp tables as of Nov. 4, 2019

This comp table provides a benchmark for private investors to evaluate existing and future investments as well as a menu for public investors to peruse.